Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EBITDA (2022 - 2025)

Historic EBITDA for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $43.0 million.

  • Indivior Pharmaceuticals' EBITDA rose 2285.71% to $43.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $158.0 million, marking a year-over-year increase of 17719.3%. This contributed to the annual value of $38.0 million for FY2024, which is 105000.0% up from last year.
  • Indivior Pharmaceuticals' EBITDA amounted to $43.0 million in Q3 2025, which was up 2285.71% from $20.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' EBITDA ranged from a high of $60.0 million in Q4 2023 and a low of -$258.0 million during Q4 2022
  • Moreover, its 4-year median value for EBITDA was $39.0 million (2023), whereas its average is -$2.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 69200.0% in 2023, then surged by 12364.86% in 2024.
  • Indivior Pharmaceuticals' EBITDA (Quarter) stood at -$258.0 million in 2022, then soared by 123.26% to $60.0 million in 2023, then fell by 23.33% to $46.0 million in 2024, then decreased by 6.52% to $43.0 million in 2025.
  • Its last three reported values are $43.0 million in Q3 2025, $20.0 million for Q2 2025, and $49.0 million during Q1 2025.